LNCaP clone FGC Cells
CAD$545.10*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
Overview of the LNCaP clone FGC cell line
| Description | The LNCaP clone FGC (Fast Growing Colonies) is an epithelial cell line that has become a cornerstone in the field of cancer research, especially in studies related to prostate cancer. The parent LNCaP cell line was established from a metastatic carcinoma of the prostate in a 50-year-old Caucasian male patient originating from a needle aspiration biopsy of the left supraclavicular lymph node. These human prostate carcinoma cells demonstrate notable tumorigenic properties in soft agar and nude mice, underlining its relevance in studying the invasive and metastatic aspects of cancer. The LNCaP clone FGC is characterized by its adherent growth pattern, often forming single cells and loosely attached clusters, its slow growth rate and a propensity to rapidly acidify the culture medium. A defining feature of the LNCaP clone FGC is its expression of key prostate cancer markers such as human prostatic acid phosphatase and prostate-specific antigen (PSA), with a strong androgen sensitivity. This sensitivity to androgens and the involvement of the androgen receptor axis in the regulation of proliferation make the prostatic cancer cell line LNCaP clone FGC an invaluable in vitro model for the study of androgen sensitivity and its implications in prostate carcinogenesis. In summary, the human prostate cancer cell line LNCaP clone FGC, with its unique characteristics and extensive utility in advanced cancer research applications, including 3D cell culture and transfection studies, continues to be highly cited and valued in the field of human cell research, providing deep insights into the molecular and cellular mechanisms underpinning prostate cancer and offering avenues for the development of novel therapeutic strategies. |
|---|---|
| Organism | Human |
| Tissue | Prostate |
| Disease | Carcinoma |
| Metastatic site | Left supraclavicular lymph node |
| Synonyms | LNCaP-Clone-FGC, LNCaP.FGC, LNCaP-FGC, LNCaP FGC, LNCAPCLONEFGC, LNCaP-ATCC |
Details
| Age | 50 years |
|---|---|
| Gender | Male |
| Ethnicity | European |
| Morphology | Epithelial |
| Growth properties | Adherent |
Specifications
| Citation | LNCaP clone FGC (Cytion catalog number 305220) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_1379 |
Genetic profile
| Karyotype | Exhibits a hypotetraploid karyotype with a modal chromosome number of 84 |
|---|
Handling of the prostatic carcinoma cell line LNCaP clone FGC
| Culture Medium | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| Supplements | Supplement the medium with 10% FBS |
| Dissociation Reagent | Accutase |
| Doubling time | 34-43 hours |
| Subculturing | Remove the old medium from the adherent cells and wash them with PBS that lacks calcium and magnesium. For T25 flasks, use 3-5 ml of PBS, and for T75 flasks, use 5-10 ml. Then, cover the cells completely with Accutase, using 1-2 ml for T25 flasks and 2.5 ml for T75 flasks. Let the cells incubate at room temperature for 8-10 minutes to detach them. After incubation, gently mix the cells with 10 ml of medium to resuspend them, then centrifuge at 300xg for 3 minutes. Discard the supernatant, resuspend the cells in fresh medium, and transfer them into new flasks that already contain fresh medium. |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality control
| Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
Certificate of Analysis (CoA)
| Lot Number | Certificate Type | Date | Catalog Number |
|---|---|---|---|
| 305220-220124 | Certificate of Analysis | 23. May. 2025 | 305220 |
-
Related products
Related products